Pangea Biomed

Pan-cancer Therapy Response Predictor

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2018
Last updated 2026-06-18
Total raised
$12.0M
Last: 2022-12
Stage
Seed
Founded
2018
Headcount
17
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Pangea Biomed is the developer of ENLIGHT, an advanced pan-cancer, pan-therapy response predictor. By combining machine learning, artificial intelligence, and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care. Pangea's unsupervised machine-learning approach makes ENLIGHT scalable and effective during the drug development process, when no clinical data is yet available.

Pangea is also developing EnlightDP, a response prediction technology based on the analysis of digital H&E slide images using its proprietary RNA expression imputation platform.

Pangea aims to bring effective precision oncology to cancer patients, improve oncology drug development, and empower oncologists to treat patients with success. Pangea is backed by NFX, and validations of its technology have been published in leading journals, including Med, Cell, Science Advances, Cancer Cell, and Nature Communications.

Funding history · 2 rounds · $12.0M total

2022-12
2022-04

Q&A

What is Pangea Biomed's primary focus?
Pangea Biomed develops ENLIGHT, an advanced pan-cancer, pan-therapy response predictor that utilizes machine learning, artificial intelligence, and deep RNA analysis to personalize cancer care.
When was Pangea Biomed founded?
Pangea Biomed was founded in March 2018.
What is the total amount of funding Pangea Biomed has raised?
Pangea Biomed has raised a total of $12,000,000.
When was Pangea Biomed's most recent funding round and who participated?
Pangea Biomed's most recent funding round was in December 2022, with participation from NFX Capital.
How many employees does Pangea Biomed have?
Pangea Biomed has 11-50 employees.
What is EnlightDP?
EnlightDP is a response prediction technology developed by Pangea Biomed that analyzes digital H&E slide images using its proprietary RNA expression imputation platform.
What is Pangea Biomed's current funding stage?
Pangea Biomed is currently in the Seed funding stage.
In which sector does Pangea Biomed primarily operate?
Pangea Biomed operates primarily in the Health Tech & Life Sciences sector.

Team · 3

Founder · Co-founder
LinkedIn ↗
Founder · Co-founder
LinkedIn ↗
Founder · Co-founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesPharmaceuticalsBiotechnology
Business model
B2B

Highlights

Verified

Tags

actionable-insightsbiotechnologyprecision-medicinetreatmentsoncologyartificial-intelligencetargeted-therapypharma-companiesdigital-healthcaredecision-supportmachine-learningimmunotherapycancerdrug-discoverylaboratoriespersonalizationclinical-trials
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)